Status:
COMPLETED
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
Lead Sponsor:
Swedish Medical Center
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Eligibility Criteria
Inclusion
- Metastatic or unresectable pancreatic cancer
- No prior chemotherapy except radiation-sensitizing doses of 5-FU
- No radiotherapy less than 4 weeks prior to the start of the study
Exclusion
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU
- Moderate to severe renal impairment
- Uncontrolled diabetes
- Inability to swallow tablets
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00316420
Start Date
December 1 2003
End Date
August 1 2009
Last Update
March 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Medical Center Cancer Institute
Seattle, Washington, United States, 98104